Cargando…

Detection of factors related to treatment reduction in docetaxel and ramucirumab for non-small cell lung cancer treatment

Treatment using docetaxel (DOC) and ramucirumab (RAM) is an effective regimen in second or later line advanced non-small cell lung carcinoma (NSCLC) treatment. However, it induces severe adverse effects, resulting in treatment reduction such as dose reduction and/or discontinuation. This study aimed...

Descripción completa

Detalles Bibliográficos
Autores principales:	Saito, Yoshitaka, Tamaki, Shinya, Hirate, Daisuke, Takada, Shinya, Takahashi, Kenta, Takekuma, Yoh, Sakakibara-Konishi, Jun, Shimizu, Yasushi, Kinoshita, Ichiro, Sugawara, Mitsuru
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10636055/ https://www.ncbi.nlm.nih.gov/pubmed/37945672 http://dx.doi.org/10.1038/s41598-023-46775-9

Ejemplares similares

Risk factor analysis for cisplatin-induced nephrotoxicity with the short hydration method in diabetic patients
por: Saito, Yoshitaka, et al.
Publicado: (2023)

Severe Hypertriglyceridemia Induced by Docetaxel: A Novel Case Report
por: Saito, Yoshitaka, et al.
Publicado: (2021)

High dose of dexamethasone attenuates docetaxel-induced fluid retention in breast cancer treatment
por: Saito, Yoshitaka, et al.
Publicado: (2023)

Impact of systemic dexamethasone dosage on docetaxel-induced oral mucositis in patients with breast cancer
por: Saito, Yoshitaka, et al.
Publicado: (2023)

Diabetes mellitus degenerates cisplatin-induced nephrotoxicity in short hydration method: a propensity score-matching analysis
por: Saito, Yoshitaka, et al.
Publicado: (2022)

Impact of reducing day 1 dexamethasone dose in anthracycline-containing regimens on acute gastrointestinal symptoms associated with breast cancer treatment
por: Saito, Yoshitaka, et al.
Publicado: (2021)

Impact of systemic dexamethasone administration on oral mucositis induced by anthracycline-containing regimens in breast cancer treatment
por: Saito, Yoshitaka, et al.
Publicado: (2022)

Pregabalin Attenuates Carboplatin-Induced Akathisia-Like Neuropathy: A Novel Case Report
por: Saito, Yoshitaka, et al.
Publicado: (2021)

Combination of Mirogabalin and Duloxetine Attenuates Peripheral Neuropathy by Eribulin: A Novel Case Report
por: Saito, Yoshitaka, et al.
Publicado: (2022)

Interstitial lung disease induced by docetaxel and ramucirumab chemotherapy after nivolumab treatment
por: Okeya, Komugi, et al.
Publicado: (2020)

Hypertriglyceridemia Induced by Fluorouracil: A Novel Case Report
por: Saito, Yoshitaka, et al.
Publicado: (2021)

Alleviation of Abdominal Pain due to Irinotecan-Induced Cholinergic Syndrome Using Loperamide: A Case Report
por: Uchiyama, Kazuki, et al.
Publicado: (2021)

Adding aprepitant to palonosetron does not decrease carboplatin-induced nausea and vomiting in patients with gynecologic cancer
por: Watanabe, Yuko, et al.
Publicado: (2021)

Temporary Severe Neutropenia during Administration of Atezolizumab: A Novel Case Report
por: Kanno, Ryota, et al.
Publicado: (2023)

Maintenance ramucirumab monotherapy after intolerable toxicities following docetaxel plus ramucirumab
por: Hata, Akito, et al.
Publicado: (2018)

Dose reduction of docetaxel avoids the usage of pegfilgrastim in docetaxel plus ramucirumab therapy for recurrent nonsmall cell lung cancer
por: Hamai, Kosuke, et al.
Publicado: (2023)

An imaging approach for determining the mechanism of enhancement of intestinal absorption of an L-theanine supplement
por: Sato, Yuki, et al.
Publicado: (2021)

Onset timing and duration of augmented renal clearance in a mixed intensive care unit
por: Mikami, Ryusei, et al.
Publicado: (2023)

Efficacy of subsequent docetaxel +/− ramucirumab and S‐1 after nivolumab for patients with advanced non‐small cell lung cancer
por: Tamura, Nobumasa, et al.
Publicado: (2019)

Improvement of renal function estimation equations for elderly Japanese people
por: Kaburaki, Soyoko, et al.
Publicado: (2018)

Association of the ward pharmacy service with active implementation of therapeutic drug monitoring for vancomycin and teicoplanin—an epidemiological surveillance study using Japanese large health insurance claims database
por: Imai, Shungo, et al.
Publicado: (2020)

A case of ramucirumab-related gastrointestinal perforation in gastric cancer with small bowel metastasis
por: Urakawa, Shinya, et al.
Publicado: (2017)

The efficacy and safety of ramucirumab plus docetaxel in older patients with advanced non‐small cell lung cancer
por: Sakaguchi, Tadashi, et al.
Publicado: (2020)

Clinical outcomes of ramucirumab plus docetaxel in the treatment of patients with non-small cell lung cancer after immunotherapy: a systematic literature review
por: Garon, Edward B., et al.
Publicado: (2023)

Validation of the usefulness of artificial neural networks for risk prediction of adverse drug reactions used for individual patients in clinical practice
por: Imai, Shungo, et al.
Publicado: (2020)

Higher incidence of acute kidney injury in patients treated with piperacillin/tazobactam than in patients treated with cefepime: a single-center retrospective cohort study
por: Kadomura, Shota, et al.
Publicado: (2019)

Serotonin Syndrome Developing Immediately after the Initiation of Low-Dose Methadone Therapy: A Case Report
por: Kumai, Masayoshi, et al.
Publicado: (2020)

Prediction and Implications of Edoxaban-Associated Bleeding in Patients after Critical Illness
por: Mikami, Ryusei, et al.
Publicado: (2023)

Retrospective cohort study of nanoparticle albumin-bound paclitaxel plus ramucirumab versus paclitaxel plus ramucirumab as second-line treatment in patients with advanced gastric cancer
por: Okunaka, Mashiro, et al.
Publicado: (2020)

Is the Efficacy of Adding Ramucirumab to Docetaxel Related to a History of Immune Checkpoint Inhibitors in the Real-World Clinical Practice?
por: Nishimura, Tadashi, et al.
Publicado: (2022)

Treatment rationale and design of the RAMNITA study: A phase II study of the efficacy of docetaxel + ramucirumab for non–small cell lung cancer with brain metastasis
por: Tanimura, Keiko, et al.
Publicado: (2018)

Therapeutic efficacy of ramucirumab after lenvatinib for post-progression treatment of unresectable hepatocellular carcinoma
por: Hiraoka, Atsushi, et al.
Publicado: (2020)

Health-related quality of life in the randomized phase 3 study of ramucirumab plus docetaxel versus placebo plus docetaxel in platinum-refractory advanced urothelial carcinoma (RANGE)
por: Necchi, Andrea, et al.
Publicado: (2020)

The role of ramucirumab with docetaxel in epidermal growth factor receptor mutant and wild-type non-small cell lung cancer
por: Ellis-Caleo, Tim, et al.
Publicado: (2021)

Phase II study of ramucirumab and docetaxel for previously treated non‐small cell lung cancer patients with malignant pleural effusion: Protocol of PLEURAM study
por: Takemoto, Shinnosuke, et al.
Publicado: (2019)

First case report of erlotinib plus ramucirumab treatment for lung carcinosarcoma with EGFR L858R mutation
por: Ishibashi, Naoya, et al.
Publicado: (2023)

Critical evaluation of ramucirumab in the treatment of advanced gastric and gastroesophageal cancers
por: ElHalawani, Hesham, et al.
Publicado: (2015)

Docetaxel plus ramucirumab with primary prophylactic pegylated-granulocyte-colony stimulating factor for pretreated non-small cell lung cancer
por: Hata, Akito, et al.
Publicado: (2018)

Improved efficacy of ramucirumab plus docetaxel after nivolumab failure in previously treated non‐small cell lung cancer patients
por: Shiono, Ayako, et al.
Publicado: (2019)

Profile of ramucirumab in the treatment of metastatic non-small-cell lung cancer
por: Cooper, Maryann R, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_8kcrbhbcbll4309s0qv40i17p5